News | July 20, 2008

Actavis Totowa Accused in Lawsuit of Producing Defective Digitek Heart Pills

July 18, 2008 - A Federal lawsuit filed in Birmingham, Alabama July 18 charges pharmaceutical company Actavis Totowa with manufacturing and distributing defective Digitek heart drug pills that allegedly contained dangerous doses of the drug’s active ingredient, digoxin, causing life-threatening adverse drug reactions.

Digitek is typically prescribed to treat irregular heartbeat or heart failure. The federal suit, filed in the wake of an FDA Digitek recall, alleges defective Digitek contained amounts of digoxin exceeding the dose set forth on the label, and in some cases exceeding the dose approved for medical treatment in humans.

The litigation, brought by a Talladega woman and her husband, alleges defective Digitek pills caused her to suffer digitalis toxicity, a some times lethal reaction to an overdose of digoxin. The suit claims the victim’s adverse reaction included a drop in heart rate into the low 30’s, blindness, confusion and incoherent speech. The suit claims the woman was hospitalized for more than a month and underwent surgery to implant an artificial heart pacemaker to treat permanent heart damage believed to be caused by Digitek overdose.

The victim’s injury occurred only a few weeks prior to April 25, 2008 when the FDA announced a nationwide recall of all Digitek tablets because of the potential that the tablets were double the appropriate thickness and contained up to twice the approved level of the active ingredient.

The suit blames Actavis for failing to heed FDA warnings in July and August of 2006 and February of 2007, that many of the drug products that were produced, manufactured and released to the public by Actavis were adulterated and as a result the drugs were not “the identity, strength, quality and purity they purport to possess.”

The suit charges the drug maker knew or should have known about the manufacturing and production defects.
Cory Watson Crowder & DeGaris is recognized nationally for its practice in mass torts litigation, multidistrict litigation and complex litigation including class actions, serious personal injuries, products liability, business and securities litigation, environmental litigation, defective medical devices and pharmaceuticals.

For more information: www.cwcd.com

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init